Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, announced that it has been notified that it will be awarded a new patent in Japan, which makes the 26th world patent for the company. The patent, which is the third one granted in Japan, recognizes the company’s patented drug-delivery technology, DehydraTECH(TM), and its ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, regardless of the “food effect,” or the presence of food in the gastrointestinal system. Drug delivery is a key component of reliable drug dosing. According to the announcement, this is the first patent issued from Lexaria’s seventh patent family and is related to tetrahydrocannabinol (“THC”). The company also noted that it has patents granted or patent applications progressing in countries around the world. Lexaria also reported that the company had submitted its briefing book to the US Food and Drug Administration (“FDA”), which was required for the upcoming pre-Investigational New Drug (“IND”) meeting that the company has requested.
To view the full press release, visit https://ibn.fm/KJSKa
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted, plus a 26th patent allowed, as well as an estimated 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.